<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030">December 31, 2019 marked the day the World Health Organization (WHO) first became aware of an infectious outbreak in the Hubei province in China, an outbreak that would quickly change the lives of people around the world [
 <xref rid="bb0005" ref-type="bibr">1</xref>]. Shortly thereafter, the causative agent was determined to be a member of the coronavirus family, now referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the coronavirus disease 2019 (COVID-19) pandemic. In the time between January 30, 2020 and March 11, 2020 the outbreak went from being classified as a Public Health Emergency of International Concern to a full-fledged global pandemic. At the time of this writing, over 1.4 million people have been afflicted by the virus worldwide and more than 80,000 people have died (https://coronavirus.jhu.edu/map.html [
 <xref rid="bb0010" ref-type="bibr">2</xref>]). Healthcare systems everywhere are preparing (and, increasingly, scrambling) to care for the exponentially growing number of patients presenting to hospitals. With the lack of any observable natural immunity in the population to this virus, and no established treatments or vaccines, management to date has been mainly supportive. That being said, researchers and clinicians are investigating and implementing a variety of therapeutics including retroviral medications such as Lopinavir /Ritonavir and Remdesivir [
 <xref rid="bb0015" ref-type="bibr">3</xref>]; combination of hydroxychloroquine and azithromycin [
 <xref rid="bb0020" ref-type="bibr">4</xref>]; and the anti-malarial drug chloroquine [
 <xref rid="bb0025" ref-type="bibr">5</xref>]. Attention has also been given to the prospect of utilizing plasma from convalescent donors to treat patients with severe COVID-19 infection [
 <xref rid="bb0030" ref-type="bibr">6</xref>,
 <xref rid="bb0035" ref-type="bibr">7</xref>].
</p>
